PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1987 June; 79(6): 1756–1763.
PMCID: PMC424518

Administration in vivo of recombinant interleukin 2 protects mice against septic death.

Abstract

Administration in vivo of recombinant interleukin 2 (rIL-2) to mice induces a polyclonal IgM response. When co-administered with a specific antigen, rIL-2 can enhance concentrations of murine IgM antibodies specific for the antigen by fivefold within 7 d of initial treatment. IgM antibodies that are induced after injection of rIL-2 include antibodies specific for J5, a cell wall core lipopolysaccharide (LPS) antigen that is shared by the different members of the Enterobactericeae family. We report here that mice pretreated with rIL-2 or immunized with J5 antigen 7 d before bacterial challenge were protected from septic death that is caused by intraperitoneal challenges with Escherichia coli. Optimal protection was provided by a combined J5 antigen and rIL-2 treatment. Acquisition of the rIL-2 and J5 antigen-induced protection against lethal bacterial infection coincided temporally with maximal serum IgM titers that also contained IgM antibodies specific for the J5 antigen. In passive immunization experiments, the affinity-purified IgM fraction in sera of rIL-2-treated animals was identified as necessary and sufficient for protection. The IgM-depleted serum had no protective effect. The nonspecific augmentation of host-defense mechanisms without the induction of endotoxin manifestations makes rIL-2 a potential candidate to any alternative LPS-containing vaccines for the prevention of bacterial infections by gram-negative organisms since the core LPS antigen is shared among gram-negative bacteria.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Finland M. Changing ecology of bacterial infections as related to antibacterial therapy. J Infect Dis. 1970 Nov;122(5):419–431. [PubMed]
  • Myerowitz RL, Medeiros AA, O'Brien TF. Recent experience with bacillemia due to gram-negative organisms. J Infect Dis. 1971 Sep;124(3):239–246. [PubMed]
  • Berry LJ. Bacterial toxins. CRC Crit Rev Toxicol. 1977 Nov;5(3):239–318. [PubMed]
  • Braude AI, Douglas H. Passive immunization against the local Shwartzman reaction. J Immunol. 1972 Feb;108(2):505–512. [PubMed]
  • Davis CE, Ziegler EJ, Arnold KF. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med. 1978 Apr 1;147(4):1007–1017. [PMC free article] [PubMed]
  • Marks MI, Ziegler EJ, Douglas H, Corbeil LB, Braude AI. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest. 1982 Apr;69(4):742–749. [PMC free article] [PubMed]
  • Ziegler EJ, Douglas H, Sherman JE, Davis CE, Braude AI. Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol. 1973 Aug;111(2):433–438. [PubMed]
  • Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. [PubMed]
  • Weyand CM, Goronzy J, Dallman MJ, Fathman CG. Administration of recombinant interleukin 2 in vivo induces a polyclonal IgM response. J Exp Med. 1986 Jun 1;163(6):1607–1612. [PMC free article] [PubMed]
  • Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. [PubMed]
  • Galanos C, Lüderitz O, Westphal O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem. 1969 Jun;9(2):245–249. [PubMed]
  • O'Hanley P, Lark D, Falkow S, Schoolnik G. Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis. J Clin Invest. 1985 Feb;75(2):347–360. [PMC free article] [PubMed]
  • Shigeta M, Takahara S, Knox SJ, Ishihara T, Vitetta ES, Fathman CG. Two independent pathways of helper activity provided by a single T cell clone. J Immunol. 1986 Jan;136(1):34–38. [PubMed]
  • Colwell DE, Michalek SM, Briles DE, Jirillo E, McGhee JR. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol. 1984 Aug;133(2):950–957. [PubMed]
  • Kirkland TN, Ziegler EJ. An immunoprotective monoclonal antibody to lipopolysaccharide. J Immunol. 1984 May;132(5):2590–2592. [PubMed]
  • Kaufman BM, Cross AS, Futrovsky SL, Sidberry HF, Sadoff JC. Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are opsonic and protect mice against lethal challenge. Infect Immun. 1986 May;52(2):617–619. [PMC free article] [PubMed]
  • ELBEIN AD, HEATH EC. THE BIOSYNTHESIS OF CELL WALL LIPOPOLYSACCHARIDE IN ESCHERICHIA COLI. I. THE BIOCHEMICAL PROPERTIES OF A URIDINE DIPHOSPHATE GALACTOSE 4-EPIMERASELESS MUTANT. J Biol Chem. 1965 May;240:1919–1925. [PubMed]
  • Miner KM, Manyak CL, Williams E, Jackson J, Jewell M, Gammon MT, Ehrenfreund C, Hayes E, Callahan LT, 3rd, Zweerink H, et al. Characterization of murine monoclonal antibodies to Escherichia coli J5. Infect Immun. 1986 Apr;52(1):56–62. [PMC free article] [PubMed]
  • Hayakawa K, Hardy RR, Honda M, Herzenberg LA, Steinberg AD, Herzenberg LA. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2494–2498. [PubMed]
  • Hayakawa K, Hardy RR, Herzenberg LA, Herzenberg LA. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J Exp Med. 1985 Jun 1;161(6):1554–1568. [PMC free article] [PubMed]
  • Greisman SE, Young EJ, DuBuy B. Mechanisms of endotoxin tolerance. 8. Specificity of serum transfer. J Immunol. 1973 Nov;111(5):1349–1360. [PubMed]
  • Williams Z, Hertogs CF, Pluznik DH. Use of mice tolerant to lipopolysaccharide to demonstrate requirement of cooperation between macrophages and lymphocytes to generate lipopolysaccharide-induced colony-stimulating factor in vivo. Infect Immun. 1983 Jul;41(1):1–5. [PMC free article] [PubMed]
  • Madonna GS, Vogel SN. Early endotoxin tolerance is associated with alterations in bone marrow-derived macrophage precursor pools. J Immunol. 1985 Dec;135(6):3763–3771. [PubMed]
  • Madonna GS, Peterson JE, Ribi EE, Vogel SN. Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun. 1986 Apr;52(1):6–11. [PMC free article] [PubMed]
  • Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. [PubMed]
  • Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985 Oct;135(4):2865–2875. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation